[{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Alembic Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mupirocin","moa":"||Isoleucine-tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Aleor Dermaceuticals \/ Alembic Pharmaceuticals Limited","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Alembic Pharmaceuticals Limited"},{"orgOrder":0,"company":"Reig Jofre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mupirocin","moa":"||Isoleucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Reig Jofre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Reig Jofre \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reig Jofre \/ Inapplicable"},{"orgOrder":0,"company":"Duke University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mupirocin","moa":"||Isoleucyl-tRNA synthetase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Duke University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Duke University \/ Bristol Myers Squibb"}]

Find Clinical Drug Pipeline Developments & Deals for T-Bact

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Duke University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Duke University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          August 07, 2024

                          Lead Product(s) : Mupirocin,Chlorhexidine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Mupirocin cream USP, 2% is indicated for the treatment of secondarily infected traumatic skin lesions due to susceptible strains of S. aureus and S. pyogenes.

                          Product Name : Mupirocin

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 17, 2021

                          Lead Product(s) : Mupirocin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Alembic Pharmaceuticals Limited

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          February 27, 2020

                          Lead Product(s) : Mupirocin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Radboud University Medical Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          Radboud University Medical Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          June 01, 2017

                          Lead Product(s) : Doxycycline,Trimethoprim,Sulfamethoxazole,Clindamycin Hydrochloride,Clarithromycin,Ciprofloxacin,Fusidic Acid,Rifampicin,Chlorhexidine,Mupirocin,Povidone Iodine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : ZonMw | Academisch Medisch Centrum - Universiteit van Amsterdam | University College, London

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Harvard Pilgrim Health Care

                          Country arrow
                          EPSC
                          Not Confirmed

                          Harvard Pilgrim Health Care

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Mupirocin,Chlorhexidine,Iodophor

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase IV

                          Sponsor : Hospital Corporation of America | University of California, Irvine | University of Massachusetts, Amherst | Rush University | Centers for Disease Control and Prevention

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          May 04, 2017

                          Lead Product(s) : Mupirocin,Chlorhexidine,Iodophor

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Hospital Corporation of America | University of California, Irvine | University of Massachusetts, Amherst | Rush University | Centers for Disease Control and Prevention

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Lindenhofgruppe AG

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lindenhofgruppe AG

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Mupirocin,Chlorhexidine

                          Therapeutic Area : Musculoskeletal

                          Study Phase : Undisclosed

                          Sponsor : Clinical Trials Unit Bern | Lindenhofstiftung | Labormedizinisches Zentrum Dr. Risch

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          September 25, 2015

                          Lead Product(s) : Mupirocin,Chlorhexidine

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Undisclosed

                          Sponsor : Clinical Trials Unit Bern | Lindenhofstiftung | Labormedizinisches Zentrum Dr. Risch

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 06, 2014

                          Lead Product(s) : Mupirocin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Horizon Health Network

                          Country arrow
                          EPSC
                          Not Confirmed

                          Horizon Health Network

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          September 25, 2013

                          Lead Product(s) : Mupirocin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          University of North Carolina, Chapel Hill

                          Country arrow
                          EPSC
                          Not Confirmed

                          University of North Carolina, Chapel Hill

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Rifampicin,Trimethoprim,Sulfamethoxazole,Minocycline Hydrochloride,Mupirocin,Chlorhexidine Gluconate,Chlorhexidine

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase II

                          Sponsor : CF Therapeutics Development Network Coordinating Center | Seattle Children’s Hospital | Washington University School of Medicine | University of Washington | University of Colorado, Denver | Baylor College of Medicine | University of Alabama at Birmingham

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 06, 2011

                          Lead Product(s) : Rifampicin,Trimethoprim,Sulfamethoxazole,Minocycline Hydrochloride,Mupirocin,Chlorhexidine Gluconate,Chlorhexidine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : CF Therapeutics Development Network Coordinating Center | Seattle Children’s Hospital | Washington University School of Medicine | University of Washington | University of Colorado, Denver | Baylor College of Medicine | University of Alabama at Birmingham

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Joseph Kim

                          Country arrow
                          EPSC
                          Not Confirmed

                          Joseph Kim

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 02, 2010

                          Lead Product(s) : Chlorhexidine Gluconate,Mupirocin,Fusidic Acid,Trimethoprim,Sulfamethoxazole,Doxycycline

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Alberta Health services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank